The shift from volume- to performance-based payment is propelling life sciences companies to seek concrete data and medical evidence – both to understand patient care and to demonstrate the effectiveness, safety and value of drug therapies.
The shift from volume- to performance-based payment is propelling life sciences companies to seek concrete data and medical evidence – both to understand patient care and to demonstrate the effectiveness, safety and value of drug therapies. To help life sciences clients better manage, analyze and share data, business analytics company SAS is launching a cloud-based, real-world data analytics platform.
The new service features de-identified integrated claims and clinical data about everyday patients receiving health care, including prescriptions and labs – data from the real world, not just trials. For the new platform, Optum, a leading information and technology-enabled health services business and part of United HealthCare, is the first collaborator and will contribute health care expertise, analytics and vast stores of clinical data to the SAS® data warehousing platform.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.